As it was based on a wider sample of unselected population ( 9), it is more reliable for the routine clinical use. Unlike TIMI, the GRACE score was derived from the Global Registry of Acute Coronary Syndrome data. Global registry for acute coronary events (GRACE) score demonstrated its superiority in the assessment of 6-months mortality risk ( 7, 8). However, the TIMI score was based on clinical studies including selected populations of patients with low comorbidity rates and it does not always reflect the reality in clinical practice. Several studies confirmed the efficacy of this index in the prognosis of mortality within 30-day period, although some attenuation was shown for patients older than 65 years ( 3- 6). Also, the TIMI score evaluates 14-day adverse events in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI). Thrombolysis in myocardial infarction (TIMI) is a simple bedside score that predicts 30-day mortality in patients with ST-elevation myocardial infarction (STEMI). Risk stratification is a useful tool for planning early treatment, discharge, and rehabilitation of ASC patients, performing research after ACS, and expediting the definitive decision about further treatment ( 1, 2).ĭifferent scores are in use for the estimation of ACS outcome. Variations in clinical appearance and outcome in patients with acute coronary syndrome (ACS) require a reliable method of risk assessment for further major adverse cardiac events (MACE) during the ACS treatment.
0 kommentar(er)
